Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis.
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients
Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients
This randomized phase II trial evaluated adding avelumab to cetuximab in RAS/BRAF wild-type metastatic colorectal cancer patients.
A new trial shows adding avelumab to cetuximab improves survival only for patients without certain genetic changes, not for everyone.
Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation grading
Shear-wave dispersion slope helps doctors grade liver inflammation in metabolic disease
This systematic review and diagnostic test accuracy meta-analysis evaluates the Shear-wave dispersion slope (SWDS) for detecting and grading…
A new analysis shows a noninvasive test can accurately detect and grade liver inflammation in patients with metabolic dysfunction-associated…
Educational programs improve self-care values in ostomized colorectal cancer patients
Educational programs boost self-care values in ostomized colorectal cancer patients
This systematic review analyzed educational intervention programs for ostomized colorectal cancer patients.
A meta-analysis of 1,011 patients found educational programs significantly improve self-care values compared to no intervention.
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
Meta-analysis finds R1 vascular margin acceptable for HCC but not CLM in minimally invasive liver surgery
Tumor margin choice matters differently for liver cancer types
This meta-analysis of 839 patients undergoing minimally invasive liver surgery found that R1 vascular margin (R1v) hepatectomy yields local …
For liver cancer, leaving a narrow margin is safe. For colorectal metastases, it raises recurrence risk.
Systematic review and meta-analysis of biopsy-guided versus clinically guided withdrawal in autoimmune hepatitis
Biopsy-guided withdrawal shows no benefit over clinical guidance for autoimmune hepatitis
This systematic review and meta-analysis evaluated relapse rates after treatment withdrawal in patients with autoimmune hepatitis.
A meta-analysis of 518 patients found that biopsy-guided withdrawal did not lower relapse rates compared to clinically guided withdrawal in …
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
Two doses of chiglitazar cut liver fat far more than a placebo in 18 weeks
In a phase II randomized, double-blind, placebo-controlled trial, 104 patients with MASLD, hypertriglyceridemia, and insulin resistance rece…
Patients with fatty liver disease and high triglycerides saw liver fat drop significantly with chiglitazar compared to placebo after 18 week…
Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
AI-Assisted Colonoscopy Improves Right-Sided Adenoma Detection in Gastroenterology Fellows
AI helps trainee doctors find more polyps in colonoscopies
This pragmatic randomized controlled trial assigned 16 gastroenterology fellows to AI-enhanced or conventional colonoscopy for 1045 procedur…
AI-assisted colonoscopy helped gastroenterology fellows detect more polyps on the right side of the colon, a hard-to-see area.
Narrative review explores ferroptosis-immune crosstalk in CNS diseases as therapeutic target
New hope for brain diseases by targeting a deadly cell death cycle
This narrative review synthesizes evidence on the interplay between ferroptosis and immune responses in CNS disorders including Alzheimer's,…
Scientists found a way to stop a deadly cell death cycle that makes brain diseases worse, offering new hope for patients with Alzheimer's an…
SABR in oligometastatic cancer showed median overall survival of 64.6 months in a single-arm phase 2 study
SABR offers five-year survival hope for patients with limited cancer spread
This single-arm phase 2 trial evaluated stereotactic ablative radiotherapy (SABR) in 380 patients with oligometastatic cancer across six Can…
Patients with few cancer spots lived longer with SABR treatment. Five-year survival reached 58.6 percent in this Canadian study.